Navigation Links
NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results
Date:3/12/2010

Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax, stated:  "During 2009, Novavax made substantial progress across every part of our business and in each of our vaccine programs.  We raised $56 million in new capital, launched a pivotal study of our 2009 H1N1 VLP pandemic influenza vaccine in Mexico with encouraging results to date, demonstrated safety and immunogenicity of our trivalent seasonal VLP influenza vaccine and identified a viable vaccine candidate to prevent respiratory syncytial virus (RSV).  We have now conducted five human clinical studies for our pandemic and seasonal VLP vaccine candidates in over 4,200 subjects, demonstrating safety and immunogenicity.  We plan to begin Phase III studies of our influenza vaccines, subject to the expected results of the ongoing Phase IIa trial in older subjects and future clinical pathway discussions with the FDA. The Company ended 2009 with a solid balance sheet and a strong scientific position that will enable us to continue to advance our pipeline products."

Key highlights of 2009:

  • Raised net proceeds of $45 million from equity sales and $11 million through a strategic alliance wi
    '/>"/>

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. NOVAVAX to Present at 22nd Annual ROTH OC Growth Stock Conference
2. NOVAVAX to Present at Cowen and Companys 30th Annual Health Care Conference
3. NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults
4. Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration
5. NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock
6. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
7. Novavax to Present at 8th Annual BIO Investor Forum 2009
8. Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico
9. NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
10. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
11. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Based on ... market, Frost & Sullivan recognizes Ventana Medical Systems, ... with the 2014 North American Frost & Sullivan ... quality practices along with a focus on innovation ... global leader in tissue-based cancer diagnostic solutions for ...
(Date:9/30/2014)... YORK , Sept. 30, 2014  Proteomics ... according to a new report from Kalorama Information.  The ... deals had occurred in proteomics in the past ... IPOs, to agreements between private proteomic companies and ... companies with novel proteomics innovator companies.  Kalorama observed ...
(Date:9/30/2014)... Sept. 30, 2014   Decision Resources Group ... data, anemic chronic kidney disease non-dialysis (CKD-ND) patients ... (ESA) medication. In addition, one-year persistency is similar ... Other key findings from the report entitled ... of Erythropoiesis Stimulating Agents in Late Stage Chronic ...
Breaking Medicine Technology:Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
(Date:9/30/2014)... September 30, 2014 Dynamic health ... hampered growth in the Bread Production industry over ... consumers to moderate their consumption of a variety ... premium varieties shrunk the market for white loaf ... proactively responded by introducing more nutritious products to ...
(Date:9/30/2014)... research team has been awarded a three-year $1.7 ... (NIH) to develop new imaging technologies and data ... how large networks of neurons in the brain ... help researchers identify the precise interactions between millions ... and speaking, and alterations in these interactions that ...
(Date:9/30/2014)... 2014 The American Diabetes Association ... diabetics curb their sweet tooth, but the most recent ... September, suggests that zero-calorie sweeteners may actually be linked ... , The Weizmann Institute of Science in Israel ... to mice, the mice developed glucose intolerance. They then ...
(Date:9/30/2014)... Tampa, FL (PRWEB) September 30, 2014 ... doors to two new clinics in Nashville, Tennessee. RMS ... Sleep Apnea Institute, and the expansion of a new ... the introduction of the Sleep Apnea Institute to Nashville, ... that suffer from sleep apnea: both diagnosed and undiagnosed. ...
(Date:9/30/2014)... News) -- Medicare should cover low-dose computed tomography lung ... disease, a coalition of more than 60 patient and ... Lung Cancer Alliance, the Society of Thoracic Surgeons, the ... the American Society of Clinical Oncology, made its point ... for Medicare & Medicaid Services (CMS). Such screening ...
Breaking Medicine News(10 mins):Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... Benedict XVI’s intention of soliciting a report on the acceptability ... //in exceptional cases, such as, in the event of either ... life within the precincts of marriage. ,Experts have commended ... issue such as this, while also agreeing that such an ...
... on its last lap of seeking enrollment from drug companies, and ... with three major insurance players. ,United Health Group seems to ... endorsers and a financial agreement with them to support the company. ... Medicare. ,80 companies have been in the fray with ...
... mother’s heart disease rather than the father’s tend to pose ... history of coronary disease//. ,The results of the ... American Journal of Preventive Medicine. This could help to better ... coronary problems as well as show early signs of the ...
... getting known for its severe dearth of general practitioners, further ... in the throes of a severe GP crisis. ,The ... the current trend of Doctors, gravitating to specialist sectors, which ... GP sector lean and totally understaffed. ,Dr Catherine ...
... been accused of the murder of three family members whose ... court appearance. // ,The victims were Marc Richardson, ... and a funeral visitation has been planned for them today ... Toussaint Church in Sudbury. ,The girl's boyfriend, an ...
... The World Health Organization WHO has recently released its ... // The United Nations health agency found that ... they are adequately nurtured and they claimed that the ... ,The W.H.O. says it now has scientific evidence ...
Cached Medicine News:Health News:Risk of Heart Disease Greater from Mom than Dad 2Health News:An International Growth Standard For Childs Releases By WHO 2
... 2 60-ms bursts of 50 Hz separated by .75 ... Tetanus: 50 Hz (50 pulses/s) or 100 Hz (100 ... Output Current: Adjustable from 0-70 mA , Stimulus ... Battery LED (green) indicates that the units on; it ...
Anesthesia Associates Nerve Stimulator Model AA 1050...
... newest peripheral nerve stimulator from B. Braun Medical. ... providing advanced digital technology. , ,Your ability ... allows the localization of practically all mixed nerves ... ,An additional optional component for the HNS11 is ...
... original MS-III design the new ... keypad and battery ... MS-IV peripheral nerve stimulator can ... in operating room, post anesthesia ...
Medicine Products: